We also identified genes with associated medications which, although not aimed at treating depression, may provide unpredicted drug benefits or adverse effects for those with the disorder. The Neuregulin 1 (NRG1) receptor ErbB4, found on GABAergic neurones, has been identified as a potentially druggable target for depression, anxiety and schizophrenia 45. There is interest in developing agents, such as basimglurant and fenobam, as antidepressants and anxiolytics that target glutamatergic receptors 46. Estrogen Receptor 2 (ESR2) has previously been implicated in antidepressant action through up-regulation by 3β-hydroxysteroid dehydrogenase 47. Estrogenic compounds have also been found to have antidepressant effects in rodent models of depression 48.
